What is the stock price of Omeros Corp?
Sarah Silva
Updated on February 07, 2026
What is the stock price of Omeros Corp?
Omeros (OMER) delivered earnings and revenue surprises of 36.36% and 6.49%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock? Omeros Corp. operates as a biopharmaceutical company.
What is the estimated return on Omer stock?
Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected. Omeros (OMER) announces initial results from a phase I study of OMS906.
What makes Omeros a world-class medical company?
At Omeros, we are proud of our innovative and cutting-edge science. Our world-class team has achieved scientific advances that no other group has been able to accomplish, delivering wholly new classes of therapeutics to benefit patients. We let science lead the way.
Who are the members of the Omeros team?
The Omeros team is exceptionally talented, passionate, collaborative and diverse. We hire smart, creative and hard-working people who want to play a meaningful part in building a preeminent biopharmaceutical company.
Omeros (OMER) delivered earnings and revenue surprises of 36.36% and 6.49%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock? Omeros Corp. operates as a biopharmaceutical company.
Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected. Omeros (OMER) announces initial results from a phase I study of OMS906.
Who is investigating Omeros Corporation for securities fraud?
Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980. The investigation concerns whether Omeros and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
Who is Pomerantz LLP investigating Omeros Corporation?
Pomerantz LLP is investigating claims on behalf of investors of Omeros Corporation (“Omeros” or the “Company”) (OMER). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext.
